Search results
Showing 61 to 75 of 201 results for dementia
compared with usual care on quality of life (for the person living with dementia and for their carers) and the timing of entry to...
This guideline covers managing cataracts in adults aged 18 and over. It aims to improve care before, during and after cataract surgery by optimising service organisation, referral and surgical management, and reducing complications. It further aims to improve the availability of information for people with cataracts before, during and after cataract surgery.
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
mum, Shazia, is overwhelmed as she also cares for her own mother who has dementia. Back to top
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
This guideline covers the clinical care of adults (18 years and over) who are dying during the last 2 to 3 days of life. It aims to improve end of life care for people in their last days of life by communicating respectfully and involving them, and the people important to them, in decisions and by maintaining their comfort and dignity. The guideline covers how to manage common symptoms without causing unacceptable side effects and maintain hydration in the last days of life.
prevalence of risk and protective factors in mid-life for the development of dementia, disability and frailty, and what are the...
This quality standard covers admissions into, and discharge from, inpatient hospital settings for adults (aged 18 years and over) with social care needs. It describes high-quality care in priority areas for improvement.
View quality statements for QS136Show all sections
Sections for QS136
- Quality statements
- Quality statement 1: Information sharing on admission
- Quality statement 2: Comprehensive geriatric assessment
- Quality statement 3: Coordinated discharge
- Quality statement 4: Discharge plans
- Quality statement 5: Involving carers in discharge planning
- Update information
- About this quality standard
Biographies for all current members of the diagnostics advisory committee.
Biographies for all current members of the diagnostics advisory committee.
mid-life maintain or adopt healthy behaviours and build up resilience to dementia, disability and frailty? What are the best methods for...
behavioural risk? What is the programme's effect on the development of dementia, disability and frailty? How feasible is extending the...
The complete list of all our published indicators, for measuring outcomes that reflect the quality of care or processes, linked by evidence to improved outcomes.
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)
Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children.
This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186